HR 3680 RFS 
(4) PRESCRIBING.—For purposes of this section 
and section 3, the term ‘‘prescribing’’ means, with 
respect to an opioid overdose reversal drug, such as 
naloxone, the practice of prescribing such drug— 
(A) in conjunction with an opioid prescrip-
tion for patients at an elevated risk of overdose; 
(B) in conjunction with an opioid agonist 
approved under section 505 of the Federal 
Food, Drug, and Cosmetic Act (21 U.S.C. 355) 
for the treatment of opioid abuse disorder; 
(C) to the caregiver or a close relative of 
patients at an elevated risk of overdose from 
opioids; or 
(D) in other circumstances, as identified 
by the Secretary, in which a provider identifies 
a patient is at an elevated risk for an inten-
tional or unintentional drug overdose from her-
oin or prescription opioid therapies. 
(b) APPLICATION.—To be eligible to receive a grant 
under this section, an eligible entity shall submit to the 
Secretary of Health and Human Services, in such form 
and manner as specified by the Secretary, an application 
that describes— 
(1) the extent to which the area to which the 
entity will furnish services through use of the grant 
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS
HR 3680 RFS 
is experiencing significant morbidity and mortality 
caused by opioid abuse; 
(2) the criteria that will be used to identify eli-
gible patients to participate in such program; and 
(3) how such program will work to try to iden-
tify State, local, or private funding to continue the 
program after expiration of the grant. 
(c) USE OF FUNDS.—An eligible entity receiving a 
grant under this section may use the grant for any of the 
following activities, but may use not more than 20 percent 
of the grant funds for activities described in paragraphs 
(4) and (5): 
(1) To establish a program for prescribing 
opioid overdose reversal drugs, such as naloxone. 
(2) To train and provide resources for health 
care providers and pharmacists on the prescribing of 
opioid overdose reversal drugs, such as naloxone. 
(3) To establish mechanisms and processes for 
tracking patients participating in the program de-
scribed in paragraph (1) and the health outcomes of 
such patients. 
(4) To purchase opioid overdose reversal drugs, 
such as naloxone, for distribution under the program 
described in paragraph (1). 
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS
HR 3680 RFS 
(5) To offset the co-pays and other cost sharing 
associated with opioid overdose reversal drugs, such 
as naloxone, to ensure that cost is not a limiting fac-
tor for eligible patients. 
(6) To conduct community outreach, in con-
junction with community-based organizations, de-
signed to raise awareness of prescribing practices, 
and the availability of opioid overdose reversal 
drugs, such as naloxone. 
(7) To establish protocols to connect patients 
who have experienced a drug overdose with appro-
priate treatment, including medication assisted 
treatment and appropriate counseling and behavioral 
therapies. 
(d) EVALUATIONS BY RECIPIENTS.—As a condition 
of receipt of a grant under this section, an eligible entity 
shall, for each year for which the grant is received, submit 
to the Secretary of Health and Human Services informa-
tion on appropriate outcome measures specified by the 
Secretary to assess the outcomes of the program funded 
by the grant, including— 
(1) the number of prescribers trained; 
(2) the number of prescribers who have co-pre-
scribed an opioid overdose reversal drug, such as 
naloxone, to at least one patient; 
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS
HR 3680 RFS 
(3) the total number of prescriptions written for 
opioid overdose reversal drugs, such as naloxone; 
(4) the percentage of patients at elevated risk 
who received a prescription for an opioid overdose 
reversal drug, such as naloxone; 
(5) the number of patients reporting use of an 
opioid overdose reversal drug, such as naloxone; and 
(6) any other outcome measures that the Sec-
retary deems appropriate. 
(e) REPORTS BY SECRETARY.—For each year of the 
grant program under this section, the Secretary of Health 
and Human Services shall submit to the appropriate com-
mittees of the House of Representatives and of the Senate 
a report aggregating the information received from the 
grant recipients for such year under subsection (d) and 
evaluating the outcomes achieved by the programs funded 
by grants made under this section. 
SEC. 3. PROVIDING INFORMATION TO PRESCRIBERS IN 
CERTAIN FEDERAL HEALTH CARE AND MED-
ICAL FACILITIES ON BEST PRACTICES FOR 
PRESCRIBING OPIOID OVERDOSE REVERSAL 
DRUGS. 
(a) IN GENERAL.—Not later than 180 days after the 
date of enactment of this Act, the Secretary of Health and 
Human Services (in this section referred to as the ‘‘Sec-
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS
HR 3680 RFS 
retary’’) may, as appropriate, provide information to pre-
scribers within federally qualified health centers (as de-
fined in paragraph (4) of section 1861(aa) of the Social 
Security Act (42 U.S.C. 1395x(aa))), and the health care 
facilities of the Indian Health Service, on best practices 
for prescribing opioid overdose reversal drugs, such as 
naloxone, for patients receiving chronic opioid therapy, pa-
tients being treated for opioid use disorders, and other pa-
tients that a provider identifies as having an elevated risk 
of overdose from heroin or prescription opioid therapies. 
(b) NOT ESTABLISHING A MEDICAL STANDARD OF 
CARE.—The information on best practices provided under 
this section shall not be construed as constituting or estab-
lishing a medical standard of care for prescribing opioid 
overdose reversal drugs, such as naloxone, for patients de-
scribed in subsection (a). 
(c) ELEVATED RISK OF OVERDOSE DEFINED.—In 
this section, the term ‘‘elevated risk of overdose’’ has the 
meaning given such term by the Secretary, which— 
(1) may be based on the criteria provided in the 
Opioid Overdose Toolkit published by the Substance 
Abuse and Mental Health Services Administration 
(SAMHSA); and 
(2) may include patients on a first course opioid 
treatment, patients using extended-release and long- 
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS
HR 3680 RFS 
acting opioid analgesics, and patients with a res-
piratory disease or other co-morbidities. 
SEC. 4. AUTHORIZATION OF APPROPRIATIONS. 
There is authorized to be appropriated to carry out 
this Act $5,000,000 for the period of fiscal years 2017 
through 2021. 
SEC. 5. CUT-GO COMPLIANCE. 
Subsection (f) of section 319D of the Public Health 
Service Act (42 U.S.C. 247d–4) is amended by inserting 
before the period at the end the following: ‘‘(except such 
dollar amount shall be reduced by $5,000,000 for fiscal 
year 2018)’’. 
Passed the House of Representatives May 11, 2016. 
Attest: 
KAREN L. HAAS, 
Clerk. 
VerDate Sep 11 2014 
02:48 May 13, 2016
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H3680.RFS
H3680
emcdonald on DSK67QTVN1PROD with BILLS